Please use this identifier to cite or link to this item:
|Title:||Sites of actions of alpha 2 agonists in the brain and periphery.||Austin Authors:||Louis, William J ;Jarrott, B;Conway, Elizabeth L||Affiliation:||Clinical Pharmacology and Therapeutics Unit, Austin Hospital, Heidelberg, Victoria, Australia||Issue Date:||24-Feb-1988||Publication information:||The American Journal of Cardiology; 61(7): 15D-17D||Abstract:||Alpha 2 agonists including rilmenidine, clonidine and alpha methylnoradrenaline all seem to have a predominantly central action in lowering blood pressure. Studies using the peripheral decarboxylase inhibitor alpha-methyldopa hydrazine in both experimental animals and humans support the predominant central action of the active metabolite of methyldopa, alpha methylnoradrenaline. Comparative studies on the antihypertensive potency of selective alpha 2 agonists like rilmenidine, guanfacine, clonidine and lofexidine suggest that the relative ability to bind to alpha 1 and alpha 2 adrenoceptors is not critical but the ability to enter the central nervous system is essential for antihypertensive efficacy.||Gov't Doc #:||2894151||URI:||http://ahro.austin.org.au/austinjspui/handle/1/12882||URL:||https://pubmed.ncbi.nlm.nih.gov/2894151||Type:||Journal Article||Subjects:||Adrenergic alpha-Agonists.pharmacokinetics.pharmacology
Blood Pressure.drug effects
Receptors, Adrenergic, alpha.metabolism.physiology
|Appears in Collections:||Journal articles|
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.